酯蟾毒配基选择性杀伤肿瘤细胞的研究  

Study on the selective cancer cell killing by resibufogenin

作　　者：唐信威[1] 肖洁[2] 宋健[2] 邹强[1] 汪瑞雪[1] 李晏齐[1] 阳泰[1] 

机构地区：[1]成都医学院科研实验中心,四川成都610083 [2]中国人民解放军成都军区总医院输血科,四川成都610083

出　　处：《中国癌症杂志》2012年第3期196-199,共4页China Oncology

基　　金：教育部科学技术研究重点项目资助(No:209104);教育部新世纪优秀人才支持计划资助(No:NCET-09-0888);四川省青年科技基金资助项(No:2010A08-443);成都医学院大学生创新实验项目(No:CX-201105)

摘　　要：背景与目的:酯蟾毒配基是我国传统抗肿瘤中药-蟾酥主要成分之一。前期的研究表明,酯蟾毒配基能在不影响静息人外周血单个核细胞(peripheral blood mononuclear cell,PBMC)存活的浓度下杀伤肿瘤细胞,本研究将进一步探讨酯蟾毒配基是否具有选择性杀伤肿瘤细胞的作用。方法:分别将酯蟾毒配基作用于Jurkat细胞、Hep3B细胞、PBMC以及PHA活化后PBMC。采用CCK-8显色法对肿瘤细胞生长抑制率进行测定;利用流式细胞术对药物作用PBMC前后细胞数量进行精确计数。结果:酯蟾毒配基对Jurkat和Hep3B肿瘤细胞有明显杀伤作用,而对静息PBMC细胞影响轻微。喜树碱、多柔比星和依托泊苷同酯蟾毒配基相似,对静息的PBMC没有影响,却能杀伤PHA活化后的PBMC。结论:酯蟾毒配基同其他抗肿瘤药物一样,都作用于肿瘤细胞增殖环节,而非选择性杀伤肿瘤细胞;强心苷类化合物选择性杀伤肿瘤细胞的观点不确切。Background and purpose： Resibufogenin is a major compound of Chinese traditional anticancer drugtoad venom. The previous study had shown that RBG could kill cancer cells but had no toxicity to PBMC. In this study, the selective cancer cells killed by RBG was further investigated. Methods： Toxicity of RBG on Jurkat, Hep3B, PBMC and PHA-stimulated PBMC was analyzed. Cancer cell survival curves were calculated by CCK-8 colorimetric assay. PBMC survival exposed to drug was analyzed by FCM. Results： RBG could obviously inhibit the growth of Jurkat and Hep3B cells. The concentration levels of camptothecin, adriamycin, and etoposide including RBG showed no toxicity to PBMC but have obvious toxicity to PHA stimulated PBMC. Conclusion： RBG like other anticancer drugs targeted on tumor cell proliferation phase. Taken together, the previous study concluded cardiac glycosides selectively kill cancer cell is incorrect.

关 键 词：酯蟾毒配基 强心苷类化合物 选择性杀伤 肿瘤细胞 

分 类 号：R733.61[医药卫生—肿瘤]